Show simple item record

Comparison of daunorubicin and anthrapyrazolone sensitivity and transport in resistant cell lines.

dc.contributor.authorMcGown, Alan T
dc.contributor.authorPoppitt, D G
dc.contributor.authorFox, Brian W
dc.date.accessioned2010-11-06T12:15:23Z
dc.date.available2010-11-06T12:15:23Z
dc.date.issued1987-12
dc.identifier.citationComparison of daunorubicin and anthrapyrazolone sensitivity and transport in resistant cell lines. 1987, 56 (6):752-4 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid3435702
dc.identifier.urihttp://hdl.handle.net/10541/114846
dc.description.abstractTwo P388 cell lines with acquired resistance to daunorubicin have been shown to exhibit cross-resistance to anthrapyrazolone (NSC 357885). The degree of cross-resistance observed in these cell lines (58 and 150 fold) is similar to those observed towards daunorubicin (34 and 142 fold). However the decreased drug accumulation observed for daunorubicin in the resistant cell lines (4-6 fold) is not observed for anthrapyrazolone. Similarly, verapamil can increase daunorubicin accumulation in resistant cells but has no effect on anthrapyrazolone accumulation. It is concluded that in contrast to daunorubicin, decreased anthrapyrazolone accumulation is not the resistance mechanism operative in daunorubicin resistant cell lines towards anthrapyrazolone.
dc.language.isoenen
dc.subjectAnticancerous Agentsen
dc.subjectCultured Tumour Cellsen
dc.subjectExperimental Leukaemiaen
dc.subjectLeukaemia P388en
dc.subject.meshAnimals
dc.subject.meshAnthraquinones
dc.subject.meshAntineoplastic Agents
dc.subject.meshDaunorubicin
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDrug Resistance
dc.subject.meshLeukemia P388
dc.subject.meshLeukemia, Experimental
dc.subject.meshMice
dc.subject.meshPyrazoles
dc.subject.meshPyrazolones
dc.subject.meshTime Factors
dc.subject.meshTumor Cells, Cultured
dc.subject.meshVerapamil
dc.titleComparison of daunorubicin and anthrapyrazolone sensitivity and transport in resistant cell lines.en
dc.typeArticleen
dc.contributor.departmentDepartment of Experimental Chemotherapy, Paterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractTwo P388 cell lines with acquired resistance to daunorubicin have been shown to exhibit cross-resistance to anthrapyrazolone (NSC 357885). The degree of cross-resistance observed in these cell lines (58 and 150 fold) is similar to those observed towards daunorubicin (34 and 142 fold). However the decreased drug accumulation observed for daunorubicin in the resistant cell lines (4-6 fold) is not observed for anthrapyrazolone. Similarly, verapamil can increase daunorubicin accumulation in resistant cells but has no effect on anthrapyrazolone accumulation. It is concluded that in contrast to daunorubicin, decreased anthrapyrazolone accumulation is not the resistance mechanism operative in daunorubicin resistant cell lines towards anthrapyrazolone.


This item appears in the following Collection(s)

Show simple item record